Company intelligence / Profile preview

Hangzhou Puji Yuancheng Biomedical Technology

Zhejiang, China

Ownership: Private
Development stage: Other

Overview

PBSS-1113 targeting USP25/USP28 has reached Phase 1 clinical stage for refractory acute myeloid leukemia. CT-300 is in preclinical development for triple negative breast cancer. No reported clinical efficacy outcomes yet.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hangzhou Puji Yuancheng Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Puji Yuancheng Biomedical Technology.

Explore the full profile